DURECT CORPORATION (DRRX)
US2666055007 - Common Stock
Taking everything into account, DRRX scores 2 out of 10 in our fundamental rating. DRRX was compared to 195 industry peers in the Pharmaceuticals industry. The financial health of DRRX is average, but there are quite some concerns on its profitability. DRRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year DRRX has reported negative net income.
DRRX had a negative operating cash flow in the past year.
DRRX had negative earnings in each of the past 5 years.
In the past 5 years DRRX reported 4 times negative operating cash flow.
1.2 Ratios
DRRX's Return On Assets of -64.28% is on the low side compared to the rest of the industry. DRRX is outperformed by 68.91% of its industry peers.
DRRX has a worse Return On Equity (-280.53%) than 78.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.28% | ||
| ROE | -280.53% | ||
| ROIC | N/A |
ROA(3y)-53.11%
ROA(5y)-36.81%
ROE(3y)-130.31%
ROE(5y)-96.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DRRX has a Gross Margin of 80.56%. This is amongst the best in the industry. DRRX outperforms 84.97% of its industry peers.
DRRX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for DRRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.72%
GM growth 5Y-2.19%
2. Health
2.1 Basic Checks
DRRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DRRX has been increased compared to 1 year ago.
The number of shares outstanding for DRRX has been increased compared to 5 years ago.
DRRX has a worse debt/assets ratio than last year.
2.2 Solvency
DRRX has an Altman-Z score of -24.48. This is a bad value and indicates that DRRX is not financially healthy and even has some risk of bankruptcy.
DRRX's Altman-Z score of -24.48 is on the low side compared to the rest of the industry. DRRX is outperformed by 87.05% of its industry peers.
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -24.48 |
ROIC/WACCN/A
WACC9.78%
2.3 Liquidity
DRRX has a Current Ratio of 1.05. This is a normal value and indicates that DRRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.05, DRRX is doing worse than 86.01% of the companies in the same industry.
DRRX has a Quick Ratio of 1.05. This is a bad value and indicates that DRRX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of DRRX (0.96) is worse than 80.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 40.52% over the past year.
DRRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -57.20%.
Measured over the past years, DRRX shows a very negative growth in Revenue. The Revenue has been decreasing by -10.97% on average per year.
EPS 1Y (TTM)40.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.81%
Revenue 1Y (TTM)-57.2%
Revenue growth 3Y-34.28%
Revenue growth 5Y-10.97%
Sales Q2Q%-11.05%
3.2 Future
DRRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.20% yearly.
DRRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 76.97% yearly.
EPS Next Y23.57%
EPS Next 2Y2.14%
EPS Next 3Y-2.13%
EPS Next 5Y28.2%
Revenue Next Year20.97%
Revenue Next 2Y46.88%
Revenue Next 3Y41.43%
Revenue Next 5Y76.97%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
DRRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DRRX's earnings are expected to decrease with -2.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.14%
EPS Next 3Y-2.13%
5. Dividend
5.1 Amount
No dividends for DRRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DURECT CORPORATION
NASDAQ:DRRX (6/17/2024, 7:00:02 PM)
After market: 1.78 0 (0%)1.78
+0.13 (+7.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap55.25M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.28% | ||
| ROE | -280.53% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80.56% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)40.52%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y23.57%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-57.2%
Revenue growth 3Y-34.28%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y